Looking Ahead: Optimism, Emerging Therapies, and the Future of RRFL Care

In the final episode, 'Looking Ahead: Optimism, Emerging Therapies, and the Future of RRFL Care,' Tara Graff, DO, MS explored the following critical question:

What gives you the most optimism for your patients with relapsed or refractory follicular lymphoma looking ahead, and what gaps today do you hope are closed in the near future?

Tara Graff shared her enthusiasm for the remarkable expansion of second-line treatment options that has occurred within a single year providing community oncologists with multiple highly effective, non-chemotherapy regimens that can be meaningfully tailored to individual patient characteristics and preferences, moving definitively away from a one-size-fits-all approach and toward truly personalized RRFL care. She expressed hope that the efficacy demonstrated by these novel combinations in the second-line setting will ultimately reduce the proportion of patients who require third-line therapy altogether. Tara Graff closed with particular excitement about the emerging role of CD19-targeted bispecific antibodies as a novel sequencing option for patients who have exhausted CD20-directed therapies in earlier lines.

Throughout the conversation, the experts provide a comprehensive reflection on the field and the factors that may shape how clinicians approach care moving forward.

Thank you for watching this Insights series on follicular lymphoma. Please subscribe to our newsletter for information on upcoming video series.